CRANBURY, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that its Chairman, CEO and President, Pankaj Mohan, Ph.D., will present at the BioCentury’s Annual NewsMakers in the Biotech Industry Conference. The presentation will take place on Friday, September 9, 2016 at 2:30 p.m. ET in room 402/403 of the Millennium Broadway Hotel in New York City.
A live audio webcast of the presentation will be available on the Investors Relations section of the Company’s website, http://ir.oncobiologics.com with the replay available for two weeks following the presentation.
About Oncobiologics, Inc. and its BioSymphony™ Platform
Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Its current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. Oncobiologics is advancing its pipeline of eight biosimilar products, two of which are currently in clinical development. Led by a team of biopharmaceutical experts, Oncobiologics operates from in-house state-of-the-art fully integrated research and development, and manufacturing facility in Cranbury, New Jersey. Oncobiologics employs its BioSymphony™ Platform to address the challenges of biosimilar development and commercialization by developing high quality mAb biosimilars in an efficient and cost-effective manner on an accelerated timeline. For more information, please visit www.oncobiologics.com.
CONTACT: CONTACTS: Oncobiologics: Lawrence A. Kenyon Chief Financial Officer LawrenceKenyon@oncobiologics.com Investors and Media: Alex Fudukidis Russo Partners, LLC alex.fudukidis@russopartnersllc.com Tel.: 646-942-5632
